Skip to content


Qinlock (ripretinib) is a small molecule pharmaceutical. Ripretinib was first approved as Qinlock on 2020-05-15. It is used to treat gastrointestinal stromal tumors in the USA. The pharmaceutical is active against mast/stem cell growth factor receptor Kit and platelet-derived growth factor receptor alpha. Qinlock's patents are valid until 2040-08-12 (FDA).
Trade Name Qinlock
Common Name Ripretinib
Indication gastrointestinal stromal tumors
Drug Class Retinol derivatives; tyrosine kinase inhibitors
Get full access now